 |
|
Volume 10, Number 3 |
|
| JAK2 mutation: a thrombotic risk factor? |
Peter Rose, Editor |
An acquired point mutation, Val 617 Phe in the exon of JAK2 gene has been described in a substantial proportion of patients with myeloproliferative disorders (MPDs). Initial efforts to date have focused on identifying the mutation across the range of MPDs to see if this correlates with leukaemic transformation or disease progression. |
|
| Venous thromboembolism and malignancy |
Tina Biss BMedSci BM BS MRCP DipRCPath Specialist Registrar in Haematology; John Hanley MBChB MD MRCPath FRCP Consultant Haematologist, Newcastle-upon-Tyne Hospitals NHS Trust |
There is a well-established link between malignancy and venous thromboembolism (VTE), originally described by Professor Armand Trousseau in 1865.1 In addition to higher rates of VTE in patients with both known and occult malignancy, there is an increased risk of recurrence and complications related to anticoagulation. |
|
| Thrombotic complications of nephrotic syndrome |
Elaine C Jolly BSc(Hons) MBChB(Hons) MRCP Specialist Registrar in Nephrology, Addenbrooke’s Hospital, Cambridge |
Nephrotic syndrome (NS) is a relatively common renal diagnosis, signifying underlying glomerular disease of various aetiologies. Its relevance to other subspecialties lies in the many complications and sequelae resulting from the marked proteinuria that is part of the syndrome. |
|
| IJV thrombosis and ovarian stimulation |
Jhansi Mudanna MRCP Specialist Registrar in Haematology; Shankara Paneesha MD MRCP MRCPath Clinical Research Fellow; Peter Rose FRCP FRCPATH Consultant Haematologist, Warwick Hospital |
Internal jugular vein (IJV) thrombosis during controlled ovarian stimulation is not widely recognised. Ovarian hyperstimulation syndrome (OHSS) is a relatively common and potentially serious complication of in vitro fertilisation (IVF) and usually manifests four to five days after harvesting of eggs, with symptoms of transient lower abdominal discomfort, mild nausea, vomiting, diarrhoea and abdominal distension. |
|
| Warfarin dosing algorithm based on genetic and environmental factors |
Farhad Kamali BSc PhD FBPharmacolS Professor of Clinical Pharmacology, University of Newcastle-upon-Tyne |
Warfarin has long been used as an anticoagulant in the management of deep vein thrombosis, pulmonary embolism, atrial fibrillation and valvular heart disease. Randomised trials1 have more recently demonstrated that anticoagulant therapy can reduce the risk of ischaemic stroke attributable to atrial fibrillation; as such, anticoagulant therapy is now recommended for high-risk patients to prevent stroke. |
|
